Tryptophan metabolism: linking gut microbiota to depression
A narrative review maps how gut dysbiosis shifts tryptophan metabolism toward the kynurenine pathway, promoting neurotoxic metabolite accumulation and reduced serotonin synthesis in depression.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
Context
Depression remains a major public health burden with limited therapeutic options. The microbiota-gut-brain axis via tryptophan metabolism represents a mechanistically relevant target.
What the study showed
The abstract describes dysbiosis redirecting tryptophan to the kynurenine pathway, accumulating neurotoxic quinolinic acid and reducing 5-HT synthesis. Microbiota-derived indoles activate the aryl hydrocarbon receptor (AhR), with variable effects on blood-brain barrier integrity, neuroinflammation, and HPA axis function. Reviewed interventions include dietary changes, probiotics, antibiotics, traditional Chinese medicine, fecal microbiota transplantation, and metabolite supplementation.
How it was done
Narrative review; number of included studies and systematic search period are not reported.
Risk of bias
Narrative design does not quantify heterogeneity or evidence quality of cited primary studies; the authors themselves acknowledge population heterogeneity, strain specificity, and insufficient dynamic monitoring as barriers to clinical translation. Analysis is based solely on the abstract.
What this study does NOT prove
This study does not demonstrate clinical efficacy of any tryptophan metabolism intervention for the treatment or prevention of depression.
In clinical practice
No intervention targeting the tryptophan-microbiota axis can be recommended in practice based on this review alone. The abstract outlines research directions, not validated protocols.
Limitations
Narrative design does not quantify heterogeneity or evidence quality of cited primary studies; the authors themselves acknowledge population heterogeneity, strain specificity, and insufficient dynamic monitoring as barriers to clinical translation. Analysis is based solely on the abstract.
Technical appendix
Version history
- 1.0 · 2026-11-11 — Auto-generated under Evidence Standard v1.0